SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceXs quarterly results and outlook are driving attention, with traders focused on rapid AI-compute growth, a return to profitability and plans for heavy infrastructure spending. Bulls see the results as evidence of an expanding AI business, while skeptics question the valuation, cash demands and potential share-unlock pressure; preliminary Tesla merger discussions add another speculative theme.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix shares are under pressure after its quarterly profit beat expectations, but a softer fourth-quarter outlook and slowing revenue growth overshadowed the results; the company also lowered its advertising revenue forecast. Bears see growth and ad execution as key concerns, while bulls argue the selloff overstates the risk given the profitable quarter and share buybacks.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Reported Chinese orders for Nvidias export-compliant GPUs are renewing discussion of strong AI-chip demand, though traders are frustrated that the news has not translated into a stronger share-price response. The debate also reflects optimism about continued AI infrastructure spending after SpaceX and Super Micro updates, balanced by worries about valuations, financing, and whether that spending will generate returns.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros preliminary fiscal Q1 update sharply raised its sales outlook and projected improved gross margins, citing stronger AI-platform demand. Bulls welcomed the upside surprise and speculated about short covering, while skeptics questioned whether the gains and improved margins would hold.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energys upcoming Q3 earnings are the main focus, with traders debating whether results and guidance can justify its premium valuation after a sharp, volatile pullback. Bulls point to fuel-cell demand from AI data centers and recent power-project deals, while skeptics warn that expectations are high and the broader AI selloff could keep shares under pressure.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS shares sharp rebound has traders focused on the anticipated 80th-event trigger and final analysis of its Phase 3 REGAL AML trial, with some also speculating about a buyout. The event count and trial results remain unconfirmed; bullish expectations of a major catalyst are countered by skepticism that the move is trading momentum without new data.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Traders are focused on potential DefenCath reimbursement upside after the HHS kidney-care plan highlighted barriers to financing dialysis innovation, which they see as support for CorMedixs request for a separate infection-prevention payment category. CMS action remains uncertain, and the discussion also weighs DefenCaths adoption and pricing against competition; REZZAYOs FDA priority review is another cited growth catalyst.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is being swept up in a semiconductor selloff as traders question the returns and financing behind AI infrastructure spending; Hock Tans casino remarks have added to skepticism. The community is split between dip-buyers pointing to continuing AI-chip demand and bearish traders focused on AVGOs weak performance, credit concerns, and the risk of further declines.

Tema ETF Trust - Tema Space Innovators ETF

Tema Space Innovators ETF

NASA is drawing attention after sliding to a 52-week low amid persistent weakness in the space sector and disappointment with the ETFs performance after the space-trade hype faded. Traders are split between calling it oversold and averaging down versus rotating into individual space names such as Rocket Lab, AST SpaceMobile, or SpaceX.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Traders are focused on Seas reported plans for a Monee fintech listing and a new AI cloud business, with the announcements coinciding with a sharp selloff. The community is split between seeing the moves as potential value creation and worrying about uncertainty, spending, and Shopee competition; some also view the decline as an oversold buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock

Equity

Immix Biopharma’s latest clinical results showed strong patient responses to its lead CAR-T candidate as the biotech firm prepares for a planned regulatory filing in 2027.

Immix Biopharma's NXC-201 Shows 89% Complete Response Rate In AL Amyloidosis

(RTTNews) - Tuesday, Immix Biopharma (IMMX) said an interim Phase 2 NEXICART-2 update showed an 89% complete response rate with investigational NXC-201 in relapsed/refractory AL amyloidosis...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX PR Newswire NEW YORK, Aug. 6, 2026 NEW YORK, Aug. 6, 2026 /PRNewswire...

IMMX Investors Have Opportunity to Join Immix Biopharma, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Immix Biopharma, Inc. (Immix or the Company) (NASDAQ: IMMX) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immix Biopharma, Inc. - IMMX PR Newswire NEW YORK, July 30, 2026 NEW YORK, July 30, 2026 /PRNewswire...

All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy

Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Immix Biopharma Analyst Bullish But Flags Safety, Adoption Questions

BofA Securities initiates Immix Biopharma with Buy rating, citing NXC-201's potential in AL amyloidosis and peak sales near $963 million.read more...

Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet

The consensus price target hints at an 113.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?

The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

What's Going On With Immix Biopharma Stock Thursday?

Immix Biopharma (IMMX) prices $150M public offering to fund its NXC-201 cell therapy into mid-2028. Read the details.read more...

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Neutral Sentiment

<ul class="summary-bullets"><li>BofA raised its price target on Immix to $30 from $27 while maintaining a ‘Buy’ rating, according to The Fly&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>NXC-201 delivered an 89% complete response rate, with no relapses.</li><li>&nbsp;Immix announced a $125 million stock offering to provide additional funding for the development of NXC-201.</li></ul>Immix Biopharma (<a class="mention" data-mention="$IMMX" data-symbol-id="IMMX" href="https://stocktwits.com/symbol/IMMX" target="_blank">IMMX</a>) was in focus on Tuesday as BofA grew more confident in the prospects for its lead CAR-T therapy, NXC-201, following encouraging new clinical data in a rare disease characterized by harmful protein buildup in organs.BofA raised its price target on Immix to $30 from $27 while maintaining a ‘Buy’ rating, according to TheFly. This represents a more than 190% upside potential from current levels.Following the results, the brokerage increased its estimate of NXC-201's odds of success in relapsed/refractory AL amyloidosis. BofA also updated its cash and share count estimates to reflect Immix’s latest equity offering.Despite the positive data, <a href="https://stocktwits.com/symbol/IMMX">IMMX shares</a> were down 11% at the time of writing, and on track for their biggest monthly loss in more than two years. The <a href="https://stocktwits.com/symbol/XBI">State Street SPDR S&amp;P Biotech ETF</a> (XBI) was down 0.5%.<h2 class="st-heading-2">NXC-201 Delivers 89% Complete Response Rate</h2>On Tuesday, Immix said its NXC-201 therapy produced an 89% complete response rate, with 40 of 45 patients achieving a complete response in its Phase 2 Nexicart-2 study. All 25 patients either achieved a complete response or were MRD-negative, meaning no disease was detected using a highly sensitive test. Immix said the complete response rate could eventually rise to 98%.So far, none of the patients who achieved a complete response or became MRD-negative has relapsed, the company said. Immix plans a final readout and a Biologics License Application (BLA) submission with the U.S. Food and Drug Administration (FDA) in mid-2027. NXC-201 has already received FDA Breakthrough Therapy and Orphan Drug designations.<h2 class="st-heading-2">Immix Bolsters Cash Position</h2>Immix also priced an offering of about 11.36 million shares at $11 each, a 4% discount to the stock’s closing price on Monday. The company plans to use the gross proceeds of $125 million primarily for NXC-201 development, working capital and general corporate purposes.Immix had about $232.1 million in cash, cash equivalents and short-term investments as of June 30, plus $2.1 million in long-term Treasury investments.Beyond NXC-201, Immix’s pipeline includes IMX-110, an experimental cancer treatment that has been studied in solid tumors. The company is also developing its N-GENIUS cell-therapy platform for potential treatments across autoimmune and other immune-related diseases.<h2 class="st-heading-2">Retail Turns ‘Bullish’ Despite Slump</h2>Retail sentiment surrounding <a class="mention" data-mention="$IMMX" data-symbol-id="IMMX" href="https://stocktwits.com/symbol/IMMX" target="_blank">IMMX</a> on Stocktwits turned ‘bullish’ from ‘bearish’ over the past 24 hours, amid ‘high’ message volumes.One user said the market is reacting to the share sale since the trial data “was good.”<stembedurl>https://stocktwits.com/Fosco_/message/665334948</stembedurl>The stock has gained around 90% so far in 2026.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/space-x-could-deliver-a-q3-beat-says-ubs-here-s-what-s-expected-to-drive-growth/cZMZdXfRBgx">SpaceX Could Deliver A Q3 Beat, Says UBS — Here’s What’s Expected To Drive Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$8.91
Prev Close	$8.22
Open	$8.26
Dividend Yield	0.00%
50-Day Moving Average	$11.61
Beta	1.36
Avg. Volume	1.68M
PE Ratio	-10.12

52-Week High	$15.10
52-Week Low	$2.85
Market Capitalization	$681.46M
EPS (Annual)	-$0.893
Price to Book	2.78
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

IMMX Fundamentals